CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
ASP Isotopes›
Products & Services›
Medical Isotopes
Medical Isotopes

ASP Isotopes› offers Medical Isotopes

ProductOperating Status: Currently Offered

Medical Isotopes is ASP Isotopes' enriched isotope line for nuclear medicine, supplying Molybdenum-100, Ytterbium-176, Zinc-68, Nickel-64, and Carbon-14 precursors.

Loading
Overview

Medical Isotopes is the nuclear medicine offering of ASP Isotopes, producing enriched stable isotopes that feed the manufacture of radioisotopes used in SPECT and PET imaging and in oncology therapies such as Lutetium-177 treatment.

The line's isotopes include Molybdenum-100 for Technetium-99m generation, Ytterbium-176 for Lutetium-177, Zinc-68 for Gallium-68 and Copper-67, Nickel-64 for Copper-64, and Carbon-14 for pharmacokinetic tracing, produced with the Aerodynamic Separation Process and Quantum Enrichment technologies at the company's Pretoria facilities.

Medical Isotopes - Classification

Industry
  • Biotechnology Companies
  • Medical Organizations

Medical Isotopes - Direct Competitors

  • Actinide

    Actinide logo

    Enriched Ytterbium-176

    actinideinc.com

AttributeMedical IsotopesEnriched Ytterbium-176
ProviderASP Isotopesaspisotopes.comActinideactinideinc.comSeed
Founded20212025
Sells To—B2B
Pricing Model—Product Sales
Ownership—Venture-backed private company
Medical Isotopes

Provider ASP Isotopesaspisotopes.com

Founded 2021

Sells To —

Pricing Model —

Ownership —

Enriched Ytterbium-176

Provider Actinideactinideinc.comSeed

Founded 2025

Sells To B2B

Pricing Model Product Sales

Ownership Venture-backed private company